Publications by authors named "Hannah M Redwine"
Dame Cicely Saunders was a pioneer in palliative care and the founder of the modern hospice movement. Her visionary work, particularly in establishing St. Christopher's Hospice in 1967, reshaped the way healthcare professionals approach the care of patients with life-limiting illnesses.
View Article and Find Full Text PDFThe chronic phase of chronic myeloid leukemia (CP-CML) is characterized by the excessive production of maturating myeloid cells. As CML stem/progenitor cells (LSPCs) are poised to cycle and differentiate, LSPCs must balance conservation and differentiation to avoid exhaustion, similar to normal hematopoiesis under stress. Since BCR-ABL1 tyrosine kinase inhibitors (TKIs) eliminate differentiating cells but spare BCR-ABL1-independent LSPCs, understanding the mechanisms that regulate LSPC differentiation may inform strategies to eliminate LSPCs.
View Article and Find Full Text PDFWe discovered that the survival and growth of many primary acute myeloid leukemia (AML) samples and cell lines, but not normal CD34+ cells, are dependent on SIRT5, a lysine deacylase implicated in regulating multiple metabolic pathways. Dependence on SIRT5 is genotype-agnostic and extends to RAS- and p53-mutated AML. Results were comparable between SIRT5 knockdown and SIRT5 inhibition using NRD167, a potent and selective SIRT5 inhibitor.
View Article and Find Full Text PDFArticle Synopsis
- Myelofibrosis is a serious blood disorder linked to mutations in the JAK/STAT signaling pathway, leading to symptoms that JAK inhibitors can alleviate but do not cure.
- Researchers conducted a study to explore the role of nuclear-cytoplasmic transport (NCT) in myelofibrosis, identifying a potential new therapeutic target using cell lines and mouse models.
- The study found that inhibiting NCT significantly reduced cell viability in myelofibrosis and improved the effects of ruxolitinib, suggesting that NCT could enhance treatment outcomes for patients.
Objective: Examine therapeutic potential of a selective serotonin reuptake inhibitor (SSRI) and a norepinephrine reuptake inhibitor (NERI) in an animal model of comorbidity between epilepsy, depression-like, and impulsive-like impairments.
Methods: Epilepsy was induced in male Wistar rats by LiCl and pilocarpine. An SSRI fluoxetine (FLX), and an NERI reboxetine (RBX) were administered either alone or as a combination over 1 week.
Article Synopsis
- Researchers are investigating how some chronic myeloid leukemia (CML) patients develop resistance to tyrosine kinase inhibitors (TKIs) without mutations in the BCR-ABL1 gene, which is typically associated with this resistance.
- They used a lentiviral shRNA library to target around 5000 cell signaling genes in a CML cell line known for its resistance, identifying key genes that when knocked down, significantly affected cell growth.
- Their findings highlight RAN and XPO1 as important factors in overcoming TKI resistance, suggesting they could be potential targets for enhancing treatment effectiveness in CML patients with BCR-ABL1 kinase-independent resistance.
Large numbers of women undergo antidepressant treatment during pregnancy; however, long-term consequences for their offspring remain largely unknown. Rodents exposed to serotonin transporter (SERT)-inhibiting antidepressants during development show changes in adult emotion-like behavior. These changes have been equated with behavioral alterations arising from genetic reductions in SERT.
View Article and Find Full Text PDF